193. Prader-Willi syndrome
95 clinical trials,   104 drugs   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-023179-25-GB (EUCTR) | 13/09/2011 | 27/07/2011 | Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome | Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome | Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection. MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Byetta Product Name: Byetta Product Code: EU/1/06/362/003: 5µg (1 pen) INN or Proposed INN: exenatide | Aintree University Hospital NHS Foundation Trust | UNIVERSITY OF LIVERPOOL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom | ||||
2 | NCT01038570 (ClinicalTrials.gov) | June 2009 | 16/11/2009 | Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo | Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study | Prader Willi Syndrome | Drug: Syntocinon®/- Spray;Drug: Physiological serum (Sodium chloride) | University Hospital, Toulouse | NULL | Completed | 18 Years | N/A | All | 24 | Phase 2 | France |